Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40.Pan.CoV vaccine
- Development stage
- Phase 1
- Lead developer
- EnnoDC
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
CD40.Pan.CoV (also known as EDC.Pan.CoV) is a broad-spectrum, protein-based pan-coronavirus subunit vaccine candidate. Developed by the Vaccine Research Institute (VRI) and EnnoDC (formerly LinKinVax), the vaccine utilizes a recombinant fusion protein modality consisting of an anti-CD40 monoclonal antibody linked to conserved T- and B-cell polyepitope regions from SARS-CoV-2 and other coronaviruses. By specifically targeting the CD40 receptor on dendritic cells, the vaccine aims to direct and enhance the immune response, potentially providing more durable and broader protection against various sarbecoviruses than current vaccines. It is currently being evaluated in a Phase I/IIa clinical trial (ANRS0640s LKV-PAN-01) as a booster dose in adults, administered subcutaneously with or without the adjuvant Hiltonol (poly-ICLC).
- Other names
- CD40 pan-coronavirus vaccineCD-40 pan-coronavirus vaccineCD 40 pan-coronavirus vaccineANRS0640s LKV-PAN-01ANRS-0640s LKV-PAN-01ANRS 0640s LKV-PAN-01
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD40LG (CD40 ligand extracellular domain)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on CD40.Pan.CoV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40.Pan.CoV vaccine.